IsletOne Therapeutics develops and commercializes innovative cell therapy technology

The company is capitalizing on the fertile translational environment at the Karolinska Institute and the Karolinska University Hospital, with asset-centric operations focused on developing and protecting its innovative science and technology platform. IsletOne has secured early groundbreaking intellectual property (IP) protection for a pipeline comprising R&D programs and applications in a wide range of inflammatory and immune-mediated disorders. The company harnesses the regenerative and immuno-modulatory capabilities of mesenchymal stromal cells (MSCs) in areas with significant unmet medical need, with a focus on cardiology, transplantation, and autoimmunity/inflammation.


IsletOne’s management

IsletOne's management makes up a seasoned and start-up savvy team that contributes with complementary expertise in pre-clinical and clinical R&D, corporate strategy, IP management and development, clinical development, and financing and fundraising.

Copyright © All Rights Reserved


IsletOne AB
Hälsovägen 7,  SE-14157, Huddinge, Sweden